Owlstone Medical raises £22m in a Series E round led by Ventura Capital to accelerate diagnostic tests.
Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.
Share allotment filed at Companies House
Owlstone Medical develops non-invasive diagnostic tools that analyse volatile organic compounds in breath samples to detect diseases early.
Owlstone Medical has secured £22m in a Series E financing round led by Ventura Capital. The funding will support the ongoing development of the company breath biopsy platform and the commercialisation of diagnostic tests and devices. Additional backing for the round came from Aviva Ventures, Horizons Ventures, and the Gates Foundation.
The capital will advance clinical trials for early-stage lung cancer screening, further the launch of tests for chronic liver diseases, and support the commercialisation of hand-held breath analysers for digestive conditions. The company continues to build on its proprietary diagnostic infrastructure to address significant unmet clinical needs globally.
From the founder
"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
Billy Boyle
Co-founder and CEO at Owlstone Medical
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Categories
About the company
Owlstone Medical
Owlstone Medical creates breath biopsy technology for non-invasive disease detection.